

# CHEMO PHARMA LABORATORIES LIMITED

EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

TEL: OFF. 91-22-22078381, 22078382 • FAX: 91-22-22074294

[www.thechemopharmalaboratoriesltd.com](http://www.thechemopharmalaboratoriesltd.com)

EMAIL: [contact@thechemopharmalaboratoriesltd.com](mailto:contact@thechemopharmalaboratoriesltd.com) / [chemopharmalab@gmail.com](mailto:chemopharmalab@gmail.com)

May 24, 2014

## **Bombay Stock Exchange Ltd.**

Department of Corporate Services

25<sup>th</sup> Floor, P. J. Towers,

Dalal Street,

Mumbai - 400 001

Script ID : 506365

### **Sub: Outcome of Board Meeting held on 23<sup>rd</sup> May, 2014**

Respected Sir / Madam,

We would like to inform you that the Board of Directors of Chemo Pharma Laboratories Limited in its Meeting held on Friday, 23<sup>rd</sup> May, 2014 at 4:00 P.M at the Administrative Office of the Company at Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai; inter-alia took the following decisions:


1. Considered and approved the Audited Financial Results to be submitted to Bombay Stock Exchange under Clause 41 of the Listing Agreement for the quarter and year ended 31<sup>st</sup> March, 2014 duly reviewed by Audit Committee.
2. Considered and approved the Audited Annual Accounts for the year ended 31<sup>st</sup> March, 2014 duly reviewed by Audit Committee.
3. Annual General Meeting of the Company to be convened on Thursday, 28<sup>th</sup> August 2014 at 4.00- p.m. at the Registered Office of the Company.
4. Book closure dates to be 18<sup>th</sup> August, 2014 to 28<sup>th</sup> August, 2014 (both days inclusive)

Kindly acknowledge the receipt.

Thanking you,

Yours faithfully,

**For Chemo Pharma Laboratories Ltd.**



**Ashok Somani**  
**Director**

Encl: a/a

# CHEMO PHARMA LABORATORIES LIMITED

EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

TEL: OFF. 91-22-22078381, 22078382 • FAX: 91-22-22074294

[www.thechemopharmalaboratoriesltd.com](http://www.thechemopharmalaboratoriesltd.com)

EMAIL: [contact@thechemopharmalaboratoriesltd.com](mailto:contact@thechemopharmalaboratoriesltd.com) / [chemopharmalab@gmail.com](mailto:chemopharmalab@gmail.com)

## AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH' 2014

(Rs.in '000)

Sr No	PARTICULARS	Quarter Ended			Year to date figures for current period ended 31/03/2014	Year to date figures for the previous period ended 31/03/2013
		3 Months ended 31/03/2014	Preceeding 3 Months ended 31/12/2013	Corresponding 3 Months ended in the previous year (31/03/2013)		
		Audited	Unaudited	Audited	Audited	Audited
	<b>INCOME FROM OPERATIONS</b>					
1	(a) Net Sales / Income from Operations	-	-	-	-	-
	(b) Other operating Income	2,372	227	2,284	4,388	2,698
	<b>Total Income from operations (net)</b>	<b>2,372</b>	<b>227</b>	<b>2,284</b>	<b>4,388</b>	<b>2,698</b>
2	<b>EXPENSES</b>					
	a. Cost of materials consumed	-	-	-	-	-
	b. Purchases of stock-in-trade	-	-	-	-	-
	c. Changes in inventories of finished goods, work-in-progress and stock in trade	-	-	-	-	-
	d. Employees benefits expense	41	41	36	162	28
	e. Depreciation and amortisation expense	12	11	15	46	62
	f. Other Expenditure	90	26	14	255	685
	i) Professional Charges	494	49	39	841	88
	ii) Shares Registry Expenses	37	-	50	68	48
	<b>Total Expenses</b>	<b>674</b>	<b>127</b>	<b>154</b>	<b>1,372</b>	<b>911</b>
3	Profit / (Loss) from operations before interest, tax and Extra ordinary items (1 - 2)	1,698	100	2,130	3,016	1,787
4	Other Income	-	-	-	-	-
5	Profit/(Loss) before interest, Depreciation and extra ordinary items (3 + 4)	1,698	100	2,130	3,016	1,787
6	Finance Costs	-	-	-	-	-
7	Profit/(Loss) before tax and extra ordinary items (5 + 6)	1,698	100	2,130	3,016	1,787
8	Exceptional items	-	-	-	-	-
9	Profit/(Loss) from ordinary activities before tax (7 + 8)	1,698	100	2,130	3,016	1,787
10	Tax expenses	-	-	-	605	355
11	Profit/(Loss) from ordinary activities after tax (9 + 10)	1,698	100	2,130	2,411	1,432
12	Extraordinary items (net of tax exp Rs. )	-	-	-	-	-
13	<b>Net Profit/(Loss) for the period (11 +/- 12)</b>	<b>1,698</b>	<b>100</b>	<b>2,130</b>	<b>2,411</b>	<b>1,432</b>
14	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	15,000	15,000	15,000	15,000	15,000
15	Reserves excluding Revaluation Reserve as per Balance Sheet if previous accounting year	31,093	32,322	29,661	33,506	31,093
16	<b>i) Earning per Share (before extraordinary items of 10/- each) (not annualised)</b>					
	(a) Basic	1.13	0.07	1.42	1.61	0.95
	(b) Diluted					
17	<b>ii) Earning per Share (after extraordinary items of 10/- each) (not annualised)</b>					
	(a) Basic	1.13	0.07	1.42	1.61	0.95
	(b) Diluted					



# CHEMO PHARMA LABORATORIES LIMITED

EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

TEL: OFF. 91-22-22078381, 22078382 • FAX: 91-22-22074294

[www.thechemopharmalaboratoriesltd.com](http://www.thechemopharmalaboratoriesltd.com)

EMAIL: [contact@thechemopharmalaboratoriesltd.com](mailto:contact@thechemopharmalaboratoriesltd.com) / [chemopharmalab@gmail.com](mailto:chemopharmalab@gmail.com)

A PARTICULARS OF SHAREHOLDING						
1	Public shareholding					
	- Number of Shares	1,081,719	1,081,719	1,081,719	1,081,719	1,081,719
	- Percentage of shareholding	72.11%	72.11%	72.11%	72.11%	72.11%
2	Promoters and Promoter Group Shareholding					
	a) Pledged / Encumbered					
	- Number of Shares	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the Company)	NIL	NIL	NIL	NIL	NIL
	b) Non - Encumbered					
	- Number of Shares	418,281	418,281	418,218	418,281	418,281
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	27.89%	27.89%	27.89%	27.89%	27.89%

Particulars		3 months ended 31.03.2014
B	INVESTOR COMPLAINTS	
	Pending at the beginning of the quarter	NIL
	Received during the quarter	NIL
	Disposed of during the quarter	NIL
	Remaining unresolved at the end of the quarter	NIL

**Note :**

- 1) The audited statement for the quarter and year ended on March 31, 2014 as reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 23.05.2014. The information presented above extracted from the financial statement.
- 2) The figures of last quarter are the balance figures between the audited figures of the full financial year and published year to date figures upto the third quarter of the current financial year.
- 3) Separate segment reporting is not applicable to the Company
- 4) Previous period / year figures have been regrouped / rearranged wherever found necessary.
- 5) No investor complaints were pending in the beginning and end of quarter ended March 31, 2014

By Order of the Board  
For Chemo Pharma Laboratories Ltd.

*Ashok Gome*

Director

Place : Mumbai

Date : 23rd May, 2014



# CHEMO PHARMA LABORATORIES LIMITED

EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

TEL: OFF. 91-22-22078381, 22078382 • FAX: 91-22-22074294

www.thechemopharmalaboratoriesltd.com


EMAIL: contact@thechemopharmalaboratoriesltd.com / chemopharmalab@gmail.com

## STATEMENT OF ASSETS & LIABILITIES AS PER CLAUSE 41 OF THE LISTING AGREEMENT

SR. NO.	PARTICULARS	AS AT 31.03.2014 RUPEES	AS AT 31.03.2013 RUPEES
<b>A</b>	<b><u>EQUITY AND LIABILITIES</u></b>		
<b>1</b>	<b>SHAREHOLDERS' FUNDS</b>		
	(a) Share Capital	15,000	15,000
	(b) Reserves and Surplus	33,504	31,093
	<b>Sub Total - Shareholders' Funds</b>	<b>48,504</b>	<b>46,093</b>
<b>2</b>	<b>NON CURRENT LIABILITIES</b>		
	(a) Other Long Term Liabilities	1,197	1,197
	<b>Sub Total - Non- Current Liabilities</b>	<b>1,197</b>	<b>1,197</b>
<b>3</b>	<b>CURRENT LIABILITIES</b>		
	(a) Other Current Liabilities	486	299
	(b) Short Term Provisions	1,806	1,201
	<b>Sub Total - Current Liabilities</b>	<b>2,292</b>	<b>1,500</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>51,993</b>	<b>48,790</b>
<b>B</b>	<b><u>ASSETS</u></b>		
<b>1</b>	<b>NON CURRENT ASSETS</b>		
	(a) Fixed Assets	131	177
	(b) Non Current Investment	16,844	16,844
	(c) Non Term Loan & Advances	18,266	16,215
	<b>Sub Total - Non- Current Assets</b>	<b>35,241</b>	<b>33,236</b>
<b>2</b>	<b>CURRENT ASSETS</b>		
	(a) Cash & Cash Equivalent	1,747	2,050
	(b) Short Term Loans and Advances	15,005	13,505
	<b>Sub Total - Current Assets</b>	<b>16,752</b>	<b>15,555</b>
	<b>TOTAL - ASSETS</b>	<b>51,993</b>	<b>48,790</b>
		-	-

Consequent to the notification of Revised Schedule VI under the Companies Act, 1956, the Assets & Liabilities for the Statements year ended 31.03.2014 are prepared as per revised Schedule VI. Accordingly, the previous year figures have also been re-classified conform to this year's classification.

By Order of the Board  
For Chemo Pharma Laboratories Ltd.

  
ASHOK SOMANI  
DIRECTOR

Place: Mumbai  
Date : 23rd May, 2014

# CHEMO PHARMA LABORATORIES LIMITED

EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

TEL: OFF. 91-22-22078381, 22078382 • FAX: 91-22-22074294

[www.thechemopharmalaboratoriesltd.com](http://www.thechemopharmalaboratoriesltd.com)


EMAIL: [contact@thechemopharmalaboratoriesltd.com](mailto:contact@thechemopharmalaboratoriesltd.com) / [chemopharmalab@gmail.com](mailto:chemopharmalab@gmail.com)

## STATEMENT OF ASSETS & LIABILITIES AS PER CLAUSE 41 OF THE LISTING AGREEMENT

SR. NO.	PARTICULARS	AS AT 31.03.2014 RUPEES	AS AT 31.03.2013 RUPEES
<b>A</b>	<b><u>EQUITY AND LIABILITIES</u></b>		
<b>1</b>	<b>SHAREHOLDERS' FUNDS</b>		
	(a) Share Capital	15,000	15,000
	(b) Reserves and Surplus	33,504	31,093
	<b>Sub Total - Shareholders' Funds</b>	<b>48,504</b>	<b>46,093</b>
<b>2</b>	<b>NON CURRENT LIABILITIES</b>		
	(a) Other Long Term Liabilities	1,197	1,197
	<b>Sub Total - Non- Current Liabilities</b>	<b>1,197</b>	<b>1,197</b>
<b>3</b>	<b>CURRENT LIABILITIES</b>		
	(a) Other Current Liabilities	486	299
	(b) Short Term Provisions	1,806	1,201
	Sub Total - Current Liabilities	<b>2,292</b>	<b>1,500</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>51,993</b>	<b>48,790</b>
<b>B</b>	<b><u>ASSETS</u></b>		
<b>1</b>	<b>NON CURRENT ASSETS</b>		
	(a) Fixed Assets	131	177
	(b) Non Current Investment	16,844	16,844
	(c) Non Term Loan & Advances	18,266	16,215
	<b>Sub Total - Non- Current Assets</b>	<b>35,241</b>	<b>33,236</b>
<b>2</b>	<b>CURRENT ASSETS</b>		
	(a) Cash & Cash Equivalents	1,747	2,050
	(b) Short Term Loans and Advances	15,005	13,505
	<b>Sub Total - Current Assets</b>	<b>16,752</b>	<b>15,555</b>
	<b>TOTAL - ASSETS</b>	<b>51,993</b>	<b>48,790</b>
		-	-

Consequent to the notification of Revised Schedule VI under the Companies Act, 1956, the Assets & Liabilities for the Statements year ended 31.03.2014 are prepared as per revised Schedule VI. Accordingly, the previous year figures have also been re-classified conform to this year's classification.

By Order of the Board  
For Chemo Pharma Laboratories Ltd.



ASHOK SOMANI  
DIRECTOR

Place: Mumbai

Date : 23rd May, 2014

# BATLIBOI & PUROHIT

## Chartered Accountants

### REVIEW REPORT TO THE BOARD OF DIRECTORS OF CHEMO PHARMA LABORATORIES LIMITED

We have reviewed the accompanying statement of audited financial results of **Chemo Pharma Laboratories Ltd., ("the Company")** for the quarter ended 31<sup>st</sup> March, 2014 except for the disclosures regarding "Public Shareholding" and "Promoter and Promoter Group Shareholding" which have been traced from disclosures made by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors / committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the independent Auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of audited financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25 Interim Financial Reporting, [notified pursuant to the Company's (Accounting Standards) Rules, 2006 as (amended)] and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Mumbai  
Dated : 23<sup>rd</sup> May, 2014



For **BATLIBOI & PUROHIT**  
Chartered Accountants  
Firm Reg. No. 101048W

  
**Paresh Chokshi**  
Partner  
Membership No.33597